Skip to main content
SpringerLink
Log in

Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy

  • Chapter
  • First Online:
Antibody-Drug Conjugates

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 17))

Abstract

Antibody–drug conjugates (ADCs) have come to the age of fruition following a long period of trials and errors. Three ADCs have been approved by the Food and Drug Administration (FDA) thus far and many more are in the development pipelines. This chapter provides the current landscape of ADC drug discovery and development. It summarizes the major players and programs in ADC drug development worldwide, currently running clinical trials registered in the USA, and recently published US patents and patent applications. In addition, the cost and outcomes aspects of ADC drug therapy are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Arnon R, Sela M (1982) In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev 62:5–27

    Article  CAS  PubMed  Google Scholar 

  • Astellas R&D Pipeline (2014, Aug) http://www.astellascom/en/ir/library/pdf/1q2015_rd_enpdf. Accessed 6 Aug 2014

  • Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, G. Garcia-Manero, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H (2014) Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol 89:964–968

    Google Scholar 

  • Boyd KA, Briggs AH, Paul J, Iveson T, Midgely R, Harkin A, Bates G, Alexander L, Cassidy J (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials 12:A41

    Article  PubMed Central  Google Scholar 

  • Canellos GP (2012) Brentuximabvedotin and panobinostat: new drugs for Hodgkin’s lymphoma–can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol 30:2171–2172

    Article  CAS  PubMed  Google Scholar 

  • Center for Medicare and Medicaid Services (2013) Medicare Part B drug average sales price files. Available at http://www.cms.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/2013-October-ASP-Pricing-File.zip. Accessed July 2014

  • Cutler D (2004) Your Money or Your Life: Strong Medicine for America’s Health Care System. Oxford University Press, New York, USA

    Google Scholar 

  • DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185

    Article  PubMed  Google Scholar 

  • Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK

    Google Scholar 

  • FDA (2010) Mylotarg (gemtuzumab ozogamicin): market withdrawal. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm. Accessed 6 Aug 2014

  • Fojo T, Grady C (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $ 440 billion question. J Natl Cancer Inst 101:1044–1048

    Article  PubMed Central  PubMed  Google Scholar 

  • Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R (2014) Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized Phase III children’s oncology group trial AAML0531. J Clin Oncol 32:3021–3032

    Google Scholar 

  • Goldenberg MM (2013) Pharmaceutical approval update. PT 38:246–258

    Google Scholar 

  • Goozner M (2004) The $ 800 million pill: the truth behind the cost of new drugs. University of California Press, Oakland, California, USA

    Google Scholar 

  • Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Recher C, Chilton L, Moorman AV, Burnett AK (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986–996

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157–1163

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M (1975) The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 35:1175–1181

    CAS  PubMed  Google Scholar 

  • Hurwitz E, Arnon R, Sahar E, Danon Y (1983) A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro. Ann N Y Acad Sci 417:125–136

    Article  CAS  PubMed  Google Scholar 

  • Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932

    Article  CAS  PubMed  Google Scholar 

  • Kantarjian HM, Fojo T, Mathisen M, Zwelling LA (2013) Cancer drugs in the United States: Justum Pretium–the just price. J Clin Oncol 31:3600–3604

    Article  PubMed Central  PubMed  Google Scholar 

  • Kharfan-Dabaja MA (2014) A new dawn for gemtuzumab ozogamicin? Lancet Oncol 15:913–914

    Article  PubMed  Google Scholar 

  • Lambert JM, Chari RV (2014) Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 57:6949–6964.

    Google Scholar 

  • Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK (2013) Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy 33:93–104

    Article  CAS  PubMed  Google Scholar 

  • O’Hear C, Rubnitz JE (2014) Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback? Expert Rev Hematol 7:427–429

    Article  PubMed  Google Scholar 

  • Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. mAbs 6:34–45

    Article  PubMed Central  PubMed  Google Scholar 

  • Pazdur R (2008) Endpoints for assessing drug activity in clinical trials. Oncologist 1 (Suppl 2):19–21

    Article  PubMed  Google Scholar 

  • Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, Thorn MD, Miller DM, Drachman JG, Rudin CM (2006) A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 54:69–77

    Article  PubMed Central  PubMed  Google Scholar 

  • Rowland GF, O'Neill GJ, Davies DA (1975) Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 255:487–488

    Article  CAS  PubMed  Google Scholar 

  • Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P (2010) The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 5:e8933

    Article  PubMed Central  PubMed  Google Scholar 

  • Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631–637

    Article  CAS  PubMed  Google Scholar 

  • Smith S (2001) Technology evaluation: SGN-15, Seattle Genetics Inc. Curr Opin Mol Ther 3:295–302

    CAS  PubMed  Google Scholar 

  • Sullivan SD (2008) The promise of specialty pharmaceuticals: are they worth the price? J Manag Care Pharm 14:S3–6

    Google Scholar 

  • Thayer AM (2014) Building antibody-drug conjugates. Chem Eng News 92:13–21

    Google Scholar 

  • Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 12:CD003407

    PubMed  Google Scholar 

  • Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, A. Forero-Torres, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183–2189

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA

    Jeffrey Wang PhD

  2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, USA

    Jonathan Hirohiko Watanabe

Authors
  1. Jeffrey Wang PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Hirohiko Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey Wang PhD .

Editor information

Editors and Affiliations

  1. Western University of Health Sciences, Department of Pharmaceutical Sciences, Pomona, California, USA

    Jeffrey Wang

  2. University of Southern California, Department of Pharmacology and Pharmaceutical Sciences, Los Angeles, California, USA

    Wei-Chiang Shen

  3. University of Southern California, Department of Pharmacology and Pharmaceutical Sciences, Los Angeles, California, USA

    Jennica L. Zaro

Rights and permissions

Reprints and permissions

Copyright information

© 2015 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Wang, J., Watanabe, J. (2015). Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy. In: Wang, J., Shen, WC., Zaro, J. (eds) Antibody-Drug Conjugates. AAPS Advances in the Pharmaceutical Sciences Series, vol 17. Springer, Cham. https://doi.org/10.1007/978-3-319-13081-1_9

Download citation

Publish with us

Policies and ethics

Search

Navigation